TIBOR KOVACSOVICS, MD

Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies

Dr. Kovacsovics brings to the University of Utah extensive expertise in the clinical management of patients with hematologic malignancies, particularly acute leukemias. In his role at the University of Utah, Dr. Kovacsovics will serve as the Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies. In his role as Associate Director of Hematologic Malignancy Clinical Research in the HCI Clinical Trials Office, he will establish a phase 1 program in hematologic malignancies, coordinate clinical research in the Division and develop a Clinical-translational Research Network suitable to carry out multicenter investigator-initiated studies in hematologic malignancies, with an emphasis on correlative science. He will also develop relationships with community practices to engage community practices in HCI-based clinical trials and increase the number of patients treated on clinical trials.

Dr. Kovacsovics graduated from the University of Geneva Medical School, and was a Resident in Internal Medicine at the Clinique Médicale Thérapeutique at Geneva University Hospital, Switzerland, after which he became Chief Resident at the same institution. He also completed training as a Research Assistant at the Institute of Biochemistry at the University of Lausanne, Switzerland. He then became a Clinical and Research Fellow in Medicine, Hematology-Oncology, at Massachusetts General Hospital and Brigham and Women’s Hospital, Harvard Medical School. This was followed by positions as “Chef de Clinique” and “Médecin Associé” in the Division of Hematology at Lausanne University Hospital, Switzerland, where he set up the autologous hematopoietic stem cell transplant program. In 2004 he was recruited to the Faculty at Oregon Health Science University, where he developed a program in acute leukemia, with a focus on innovative clinical trials and molecular diagnostics. Dr. Kovacsovics has served as both principal investigator and co-investigator on numerous clinical trials and grants. Many of his clinical trials focus on new agents for treatment of acute leukemias. He is a member of multiple professional societies, and was the chairman of the Swiss Leukemia Cooperative Group (SAKK) from 2002-2004. He has published over forty peer-reviewed manuscripts, and is a regular reviewer for many top Hematology journals, including Blood, American Journal of Cancer, Haematologica, and Leukemia.